X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

ANEB

Closed

Anebulo Pharmaceuticals Inc

1.75
+0.31 (+21.53%)
Last Update: 01 Jul 2025 23:15:00
Yesterday: 1.44
Day's Range: 1.36 - 2.17
Send
When Written:
 
2.9
Anebulo Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that is focused on developing novel therapeutics to treat patients suffering from acute respiratory distress syndrome (ARDS) and other related conditions. The company's lead product candidate, APN-01, is a recombinant human angiotensin-converting enzyme 2 (rhACE2) protein that is designed to restore balance to the renin-angiotensin-aldosterone system (RAAS) and reduce lung inflammation in patients with ARDS.

Anebulo Pharmaceuticals was founded in 2017 and is headquartered in San Diego, California. The company is led by a team of experienced biotech executives and scientists, including CEO and co-founder, Dr. Peter DiLaura, who previously served as the CEO of BioElectronics Corporation, and Chief Medical Officer, Dr. David Fink, who previously served as the Chief Medical Officer of Arena Pharmaceuticals.

In addition to its work on APN-01, Anebulo Pharmaceuticals is also exploring other potential therapeutic candidates for the treatment of respiratory diseases. The company has received funding from various sources, including the National Institutes of Health (NIH) and the California Institute for Regenerative Medicine (CIRM).

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X